1.91%
33.26%
32.82%
7.32%
46.15%
50.75%
83.18%
AI Spotlight on BPMC
Company Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd.
The company was formerly known as Hoyle Pharmaceuticals, Inc.and changed its name to Blueprint Medicines Corporation in June 2011.Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 116.23 |
| Change Percentage | 1.91% |
| Open | 114.49 |
| Previous Close | 114.05 |
| Market Cap ( Millions) | 7384 |
| Volume | 10442 |
| Year High | 121.9 |
| Year Low | 72.24 |
| M A 50 | 96.88 |
| M A 200 | 97.78 |
Financial Ratios
| FCF Yield | -3.39% |
| Dividend Yield | 0.00% |
| ROE | -47.66% |
| Debt / Equity | 150.57% |
| Net Debt / EBIDTA | -158.93% |
| Price To Book | 23.52 |
| Price Earnings Ratio | -57.53 |
| Price To FCF | -29.47 |
| Price To sales | 17.0 |
| EV / EBITDA | -32.3 |
News
- Jan -14 - Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy
- Jan -14 - 5 Biotech Stocks Worth Adding to Your Portfolio in 2025
- Jan -14 - Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar?
- Jan -13 - Blueprint Medicines price target lowered by $11 at Wedbush, here's why
- Jan -12 - Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
- Dec -18 - Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -07 - Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
- Nov -29 - Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
- Nov -15 - Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
- Nov -14 - Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
- Oct -31 - BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
- Oct -30 - Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
- Oct -30 - Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
- Oct -30 - Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Oct -24 - 5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
- Oct -21 - Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Oct -16 - Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
- Oct -15 - Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know
- Sep -11 - The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join
- Sep -10 - Blueprint Medicines to Present at Upcoming Investor Conferences
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Precision Therapies
Expected Growth : 15.4 %
What the company do ?
Precision Therapies from Blueprint Medicines Corporation are targeted cancer treatments that inhibit specific genetic mutations driving cancer growth and progression.
Why we expect these perspectives ?
Growing demand for targeted cancer treatments, increasing prevalence of cancer, and advancements in genetic research drive the growth of Precision Therapies from Blueprint Medicines Corporation.
Blueprint Medicines Corporation Products
| Product Range | What is it ? |
|---|---|
| AYVAKIT | A kinase inhibitor for the treatment of systemic mastocytosis |
| GAVRETO | A RET inhibitor for the treatment of RET-altered thyroid cancers and RET fusion-positive non-small cell lung cancer |
| Praxis | A precision medicine platform for identifying and developing targeted therapies |
| Compass | A patient identification and access platform for rare genetic diseases |
Blueprint Medicines Corporation's Porter Forces
Threat Of Substitutes
The threat of substitutes for Blueprint Medicines Corporation is medium, as there are some alternative treatments available for cancer and rare genetic diseases, but they are not yet widely adopted.
Bargaining Power Of Customers
The bargaining power of customers for Blueprint Medicines Corporation is low, as patients and healthcare providers have limited negotiating power due to the company's specialized products.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Blueprint Medicines Corporation is medium, as the company relies on a few key suppliers for raw materials and manufacturing services.
Threat Of New Entrants
The threat of new entrants for Blueprint Medicines Corporation is high, as the biotechnology industry is highly competitive and new companies are emerging with innovative technologies.
Intensity Of Rivalry
The intensity of rivalry for Blueprint Medicines Corporation is high, as the company operates in a highly competitive industry with many established players and new entrants.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 84.13% |
| Debt Cost | 6.65% |
| Equity Weight | 15.87% |
| Equity Cost | 7.21% |
| WACC | 6.74% |
| Leverage | 530.11% |
Blueprint Medicines Corporation : Quality Control
Blueprint Medicines Corporation passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, … |
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| RNA | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
| KRYS | Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Avidity Biosciences
A-Score
1-Year Total Return ->
🥈
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Blueprint Medicines
A-Score
1-Year Total Return ->
4
Sarepta Therapeutics
A-Score
1-Year Total Return ->
5
Krystal Biotech
A-Score
1-Year Total Return ->
6
